• We are sorry, but NCBI web applications do not support your browser and may not function properly. More information

Appendix Table D7Event-free survival (DFS; PFS) for treatment (tandem HSCT) and comparison (single HSCT) groups: CNS/embryonal tumors

Outcome (Tumor type)Intervention Tandem (%; ± 95% CI; SE) [N]Comparator Single (%; ± 95% CI; SE) [N]P-valueStudy (record #)
2 year rate
(MB-PNET)73 (46-99) [11]67 (13-100) [3]NRSung, 2007 (4770)
(AT/RT)[One patient remained disease-free]Gidwani, 2008 (71940)
(MB-PNET)57 (15) [13]Perez-Martinez, 2005 (7650)
3 year rate
(MB-PNET)73 (46-99) [11]NASung, 2007 (4770)
(MB)49 (27-72) [21]Chi, 2004 (7900)
(AT/RT)23 (11) [13]Gardner, 2008 (71930)
(MB)67 [2 of3 patients with complete remission]Aihara, 2010, #1201
5 year rate
(MB-PNET)58 (25-91) [11]NASung, 2007 (4770)
(PNET)39 (24-53) [43]Fangusaro, 2008 (3420)
(MB)52 (11) [21]Dhall, 2008 (52130)
EFS range for 5 years for studies with > 10 patients5839-52

AT/RT, atypical teratoid/rhabdoid tumor; CC, conventional care; CI, confidence interval; DFS, disease-free survival; EFS, event-free survival; MB, medulloblastoma; N, number of patients; NA, not available; PFS, progression-free survival; PNET, supratentorial primitive Neuroectodermal tumors; SE, standard error

From: Appendix D, Disease-Free/Event-Free Survival

Cover of Hematopoietic Stem-Cell Transplantation in the Pediatric Population
Hematopoietic Stem-Cell Transplantation in the Pediatric Population [Internet].
Comparative Effectiveness Reviews, No. 48.
Ratko TA, Belinson SE, Brown HM, et al.

PubMed Health. A service of the National Library of Medicine, National Institutes of Health.